Format

Send to

Choose Destination
J Viral Hepat. 2019 Jun;26(6):770-773. doi: 10.1111/jvh.13067. Epub 2019 Feb 27.

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.

Author information

1
Ruane Medical and Liver Health Institute, Los Angeles, California.
2
AW Morrow Gastroenterology and Liver Centre, Sydney, NSW, Australia.
3
University of Auckland, Auckland, New Zealand.
4
Gilead Sciences Inc., Foster City, California.
5
Kaiser Permanente, San Diego, California.
6
University of Alberta, Edmonton, AB, Canada.

Abstract

This study evaluated 12-week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir- and velpatasvir-containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.

KEYWORDS:

direct-acting antiviral agents; hepatitis C virus; retreatment

PMID:
30663168
DOI:
10.1111/jvh.13067

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center